HbA1c and cardiac events after CABG in patients with diabetes

  • Turgeon RD & al.
  • Pharmacotherapy
  • 28 Dec 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with type 2 diabetes (T2D) who underwent coronary artery bypass grafting (CABG), achieving haemoglobin A1c (HbA1c) level 6.1-7.0% was associated with a reduced risk for major adverse coronary events (MACEs) and unstable angina compared with achieving HbA1c level >8.0% and lower risk for all-cause mortality compared with achieving an HbA1c level ≤6.0%.

Why this matters

  • Guidelines for glycaemic targets for patients with diabetes after CABG significantly vary, ranging from a target HbA1c

Study design

  • A secondary analysis of the BARI2D trial included 549 patients with T2D and coronary artery disease who underwent CABG.
  • Primary outcome: MACEs (all-cause mortality, myocardial infarction, unstable angina or repeat revascularisation after the index HbA1c level).
  • Funding: None disclosed.

Key results

  • Achieving HbA1c level >8.0% was associated with an increased risk for MACEs compared with achieving HbA1c level 6.1-7.0% (adjusted HR [aHR], 1.77; 95% CI, 1.01-3.10)
  • The risk for unstable angina was stronger among those with HbA1c level >8.0% (aHR, 5.21; 95% CI, 1.03-26.39).
  • Compared with achieving HbA1c level 6.1-7.0%, achieving HbA1c ≤6.0% was associated with an increased risk for all-cause mortality (HR, 2.41; 95% CI, 1.01-5.74).

Limitations

  • Post-hoc observational design.
  • Modest sample size limited the ability to identify difference between HbA1c categories.